Article ID Journal Published Year Pages File Type
8623734 Seminars in Arthritis and Rheumatism 2018 6 Pages PDF
Abstract
Tocilizumab, IV GC and methotrexate improve the likelihood of being relapse-free in subjects with GCA. Assessment of GC sparing strategies in GCA has long depended on imprecise trials that would change significance if outcomes were reversed for a handful of subjects. FI may be used in rheumatology to simplify communication of statistical significance and overcome limitations of p-value.
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Authors
, , , , , , , , ,